BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.

计划入组 135 人 · 首次发布于 2024 年 5 月 22 日

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

计划入组 180 人 · 首次发布于 2025 年 7 月 24 日

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

计划入组 140 人 · 首次发布于 2022 年 5 月 9 日

Pixantrone(Pixuvri)

C₁₇H₁₉N₅O₂

anti-CD22 degrader-antibody conjugates (non-Hodgkin lymphoma/NSCLC)

anti-CD19 CAR T-cell therapy (B-cell non-Hodgkin lymphoma)

The Cooper Health System, A New Jersey Non-Profit Corporation

United States

REPLIGEN CORPORATION

United States

EMCURE PHARMACEUTICALS LIMITED

United Arab Emirates

EZH2 Inhibitors Enhance Lymphoma Immunotherapy in Preclinical Models

IND Application Submitted to FDA for SynKIR-310 Trial in Relapsed/Refractory B-NHL

Study Links Long-term Tattoo Exposure to Increased Risk of Rare B-Cell Lymphomas